

EMV Capital plc
C/O Azets
Burnham Yard
London End
Beaconsfield
Buckinghamshire
HP9 2JH

THIS DOCUMENT AND THE ACCOMPANYING FORM OF PROXY ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in doubt about the contents of this document or about what action to take, you are recommended to seek your own independent professional advice immediately from your stockbroker, solicitor, accountant or other appropriate independent financial adviser duly authorised under the Financial Services and Markets Act 2000 if you are resident in the United Kingdom, or, if not, from another appropriately authorised independent financial adviser in the relevant jurisdiction.

If you sell or have sold or otherwise transferred all of your ordinary shares in the capital of EMV Capital plc ("**Ordinary Shares**"), please send this document and the accompanying Form of Proxy as soon as possible to the purchaser or transferee, or to the stockbroker, bank or other agent through whom the sale or transfer is or was effected, for delivery to the purchaser or transferee. If you have sold only part of your holding of Ordinary Shares, you should retain these documents and consult the stockbroker, bank or other agent through whom the sale was effected.

Dear Shareholder

I take pleasure in sending you the 2024 Annual Report and notice of this year's Annual General Meeting ("**Meeting**") for shareholders of EMV Capital plc, formerly NetScientific plc (the "**Company**") which will be held on Monday 30 June 2025 at 10:00 a.m. at Panmure Liberum Limited, Ropemaker Place, Level 12, 25 Ropemaker Street, London, EC2Y 9LY.

The Company is also holding a live online presentation for investors at 10:00 a.m. on 12 June 2025 on the Investor Meet Company platform. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 11 Jun 2025, 09:00 BST, or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: <https://www.investormeetcompany.com/emv-capital-plc/register-investor>. Investors who already follow the Company on the Investor Meet Company platform will automatically be invited.

Explanatory notes on all the resolutions accompany this Notice of Meeting (the "Notice") may be found on the final page of this document.

The Board of Directors of the Company (the "**Board**") believes that all the proposed resolutions set out in this Notice are in the best interests of the Company and its shareholders as a whole. The Board recommends that you vote in favour of the proposed resolutions, as each of the Directors of the Company intend to do in respect of their own beneficial shareholdings.

Financial and Operational Highlights

Group Performance

- In December 2024 EMV Capital Plc successfully executed a £1.5 million placing of ordinary shares (at a 15% premium to the previous closing price), with substantial participation by Directors and management.
- The Group's performance includes the operational core of EMV Capital plc, EMV Capital Partners and other EMV Capital operating companies, alongside subsidiary portfolio companies where the Group holds over a 50% shareholding.
- Group revenue increased to £2.5 million (2023: £1.4 million), comprising:
 - £2.0 million from EMV Capital core revenue, a strong increase of 67% (2023: £1.2 million), which covered c.58% of the core Group's costs whilst also providing infrastructure and services to the Group and its portfolio companies;

- New recurring fund management fees from Martlet Capital of £0.5 million or c.70% of the 54% annual revenue growth over prior year; and
 - £0.5 million from ProAxis (2023: £0.2 million).
- Group losses for the year were £3.7 million (2023: £2.9 million), comprising:
 - £1.5 million attributed to the 'core' of the operations of EMV Capital (2023: £1.1 million); and
 - £2.2 million attributed to the subsidiary portfolio companies ProAxis and Glycotest (2023: £1.8 million). The result includes £0.6 million (2023: £0.7 million) of non-cash impairment charges for ProAxis. In line with our capital efficient investment strategy, ProAxis and Glycotest were funded by external investors and as such, were not a cash burden to Group operations.
- Total assets decreased to £19.5 million (2023: £22.5 million), with net assets decreasing to £14.1 million (2023: £17.1 million), primarily driven by the decrease in value of the direct investments in PDS and Q-Bot.
- Divestments from PDS Biotech during the period of £0.2 million (2023: £1.4 million from PDS Biotech and Q-Bot).
- Capital efficient investments during the period of £1.0 million (2023: £0.1 million) through minimal use of cash.
- Cash on the balance sheet was £1.0 million at 31 December 2024 (2023: £0.2 million), with a further £1.4 million in readily realisable quoted securities at 31 December 2024 (2023: £4.3 million).

Assets Under Management

- Total assets under management (AUM) (including directly held assets included in the audited financial statements and those managed for third parties for which we have carried interest arrangements) increased by 33% to £98.5 million¹ (2023: £74.0 million), comprising:
 - Fair Value of direct holdings increased by 6% to £37.7 million (2023: £35.6 million). These direct holdings may be broken down as follows:
 - £13.4 million of balance sheet investments (2023: £16.4 million), the decrease in fair value is mainly attributable to Q-Bot, PDS and FOx, partly offset by increases in fair value of DeepTech Recycling and Wanda.
 - £24.3 million of subsidiaries and associates at directors' unaudited valuations (2023: £19.2 million); or
 - £36.3 million for the private unlisted portfolio (2023: £31.3 million) and £1.4 million for the public listed portfolio (NASDAQ-listed PDS) (2023: £4.3 million).
 - There was £1.9 million of new investments by EMV Capital across the portfolio (of which £0.1 million was in cash, £0.6 million was through the issue of EMV Capital plc shares and £1.2 million was in-kind investment) and a £0.2 million net increase in fair value of existing investments.
 - Fair Value of managed and third-party holdings increased by c.58% to £60.8 million (2023: £38.4 million). These indirect holdings may be broken down as follows:
 - £35.0 million (2023: £38.4 million) not included in the audited financial statements in respect of syndicated investor portfolio. The decrease of £3.4 million was mainly due to the conversion of third-party assets under management in Wanda to a direct 30% equity stake in May 2024, and the decrease in fair value of Q-Bot;
 - £24.5 million not included in the audited financial statements in respect of the newly added Martlet Capital portfolio, where EMV Capital Partners Limited (formerly EMV Capital Limited) was appointed as investment manager in May 2024;
 - £1.3 million not included in the audited financial statements in respect of our EIS Fund where EMV Capital Partners was appointed as investment manager in February 2024; and
 - There was £0.7 million not included in the audited financial statements for new investments and the fair value of existing investments decreased by £0.1 million.
- Total AUM at 31 May 2025 increased further to £103 million (unaudited), reflecting fair value uplift due to several portfolio transactions and a Martlet Capital follow-on fundraising. This is composed of Fair Value of direct holdings of £38.3 million and Fair Value of managed and third-party holdings of £64.7 million.

The geopolitical and macroeconomic uncertainties highlighted in our 2023 annual report have persisted and, in many respects intensified. The turbulent 2024 general elections and changes in governments around the world, particularly in the US and the UK, have only added to this sense of instability. Across both sides of the Atlantic,

¹ In Martlet Capital the Group holds direct equity investment, syndicated third party monies and fund management stakes which when consolidated for the Group's total AUM have been adjusted to avoid double-counting.

access to equity and debt capital remains limited for both private and public companies. Valuations of technology-rich companies continue to be volatile and have come under sustained downward pressure.

Notwithstanding these challenges, our executive team continues to demonstrate its ability to navigate adversity and complexity. During the year, we successfully launched our Fund Management practice, having secured FCA authorisation and taken on the management of the Martlet Capital fund.

As a result, the Group now benefits from a broader and more resilient revenue mix, comprising:

- recurring fund management fees;
- corporate finance and advisory income;
- board membership compensation; and
- Value Creation Services.

We have now rebranded all these activities under the 'EMV' umbrella, while continuing to promote the individual identity of funds such as Martlet Capital.

Investment performance over the last twelve months across our portfolios, both direct and managed, has been mixed, reflecting the limited opportunities for exits amid what are difficult IPO markets in the US and Europe, and subdued appetite for M&A internationally. The executive team remains very closely involved with all our portfolio companies, guiding and supporting them through the commercial and financial challenges they face. These efforts have contributed to a relatively stable overall position, helping to balance out individual challenges. The performance of each holding is detailed later in this report.

In December 2024, we completed a small equity placement for EMV Capital Plc at a 15 per cent premium to market price, to raise gross proceeds of £1.5 million. On behalf of the board, I welcome our new shareholders to the register, thank our existing shareholders for their continued support, and acknowledge the meaningful personal investments made by my fellow directors.

Looking ahead, the Directors remain confident that the Group's strategy positions us well to weather these headwinds, and benefit from market recovery as interest in our sectors improves. Challenging markets present opportunities, and our resilient investment model can adapt to changing circumstances and engage with these. EMV Capital is positioned to benefit from emerging macro-trends, including the shift to defence and other strategic industries; re-industrialisation and the move towards UK-centric production; promised increased capital flows following the Mansion House initiatives; and broader capital realignment as a result of global changes.

With a diversified and resilient revenue base, strong governance, and exposure to long-term macro trends, we believe this presents a compelling entry point for long-term investors. As market sentiment improves, we are well placed to benefit from renewed interest in high-quality, strategically positioned venture-backed businesses.

On behalf of the Board, I would like to express our gratitude to our executive directors, our dedicated EMV employees, our colleagues across our portfolio companies, and all other stakeholders for their continued support and hard work.

Yours sincerely

Dr. Charles Spicer

Chair

EMV Capital Plc

EMV CAPITAL PLC (incorporated and registered in England and Wales with registered number 08026888)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the annual general meeting (the "**Meeting**" or "**Annual General Meeting**") of EMV Capital plc (incorporated and registered in England and Wales with registered number 08026888) (the "**Company**") will be held on Monday, 30 June 2025 at 10:00 a.m. at Panmure Liberum Limited, Ropemaker Place, Level 12, 25 Ropemaker Street, London, EC2Y 9LY, United Kingdom to consider and, if thought fit, to pass the following resolutions, of which resolutions 1 to 9 will be proposed as ordinary resolutions and resolution 10 will be proposed as a special resolution.

Resolution 1

To receive and adopt the Company's Annual Report and Accounts for the financial year ended 31 December 2024, together with the Directors' Report and the Independent Auditors' Report on those accounts (together the "**Annual Report**").

Resolution 2

To receive and approve the Directors' Remuneration Report for the financial year ended 31 December 2024 as set out in the 2024 Annual Report.

Resolution 3

To reappoint BDO LLP as auditors of the Company to hold office from the conclusion of this Meeting until the conclusion of the next annual general meeting of the Company.

Resolution 4

To authorise the Audit Committee to determine the remuneration of the auditors.

Resolution 5

To confirm the re-appointment of Dr Charles Spicer (in accordance with the Articles of Association of the Company (the "**Articles**")) as a director of the Company.

Resolution 6

To confirm the re-appointment of Dr Ilian Iliev (in accordance with the Articles) as a director of the Company.

Resolution 7

To confirm the re-appointment of Edward Hooper (in accordance with the Articles) as a director of the Company.

Resolution 8

To confirm the re-appointment of Dr Jonathan Robinson (in accordance with the Articles) as a director of the Company.

Resolution 9

That, pursuant to Article 8 of the Articles, the directors be generally and unconditionally authorised, in accordance with section 551 of the Companies Act 2006 ("**Companies Act**"), to allot shares in the Company and grant rights to subscribe for or convert any security into shares in the Company:

- (a) up to an aggregate nominal amount (within the meaning of section 551(3) and (6) of the Companies Act) of £462,789 (such amount to be reduced by the nominal amount allotted or granted under (b) below in excess of £462,789); and
- (b) comprising equity securities (as defined by section 560(1) of the Companies Act) up to an aggregate nominal amount (within the meaning of section 551(3) and (6) of the Companies Act) of £925,579 (such amount to be reduced by any allotments or grants made under (a) above) in connection with or pursuant to an offer by way of a rights issue:
 - (i) to holders of ordinary shares in proportion (as nearly as may be practicable) to the respective number of ordinary shares held by them on the record date for such allotment; and

(ii) to holders of other equity securities as required by the rights of those securities or, subject to such rights, as the directors otherwise consider necessary,

but subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates, legal or practical problems in or under the laws of any territory or the requirements of any regulatory body or stock exchange,

provided that this authority shall expire at the conclusion of the next annual general meeting of the Company after the passing of this resolution or on 30 June 2026 (whichever is earlier), save that the Company may make an offer or agreement before this power expires which would or might require shares to be allotted or rights to be granted after this power expires and the directors may allot shares, or grant rights to subscribe for or to convert any security into shares, pursuant to any such offer or agreement as if this authority had not expired.

Resolution 10

That, subject to the passing of resolution 9 and pursuant to Article 8 of the Articles, the directors be given the general power pursuant to sections 570 and 573 of the Companies Act to allot equity securities (within the meaning of section 560 of the Companies Act) for cash either pursuant to the authorities granted by resolution 9 or by way of a sale of treasury shares (within the meaning of section 724(5) of the Companies Act) as if section 561(1) of the Companies Act did not apply to any such allotment or sale, provided that this power shall be limited to the allotment of equity securities for cash or sale of treasury shares:

(a) in connection with or pursuant to an offer of or invitation to acquire equity securities (whether by way of a rights issue, open offer or otherwise, but, in the case of an allotment pursuant to the authority granted by paragraph (b) of resolution 9, such power shall be limited to the allotment of equity securities in connection with an offer by way of a rights issue):

(i) to holders of ordinary shares in the capital of the Company in proportion (as nearly as practicable) to the respective numbers of ordinary shares held by them on the record date for such allotment or sale; and

(ii) to holders of other equity securities in the capital of the Company, as required by the rights of those securities or, subject to such rights, as the directors otherwise consider necessary,

but subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates or any legal or practical problems under the laws of any territory or the requirements of any regulatory body or stock exchange; and

(b) otherwise than pursuant to paragraph (a) of this resolution, up to an aggregate nominal amount of £277,673,

and this power shall expire at the conclusion of the next annual general meeting of the Company after the passing of this resolution or on 30 June 2026 (whichever is the earlier), save that the Company may make an offer or agreement before this power expires which would or might require equity securities to be allotted for cash, or treasury shares to be sold, after this power expires and the directors may allot equity securities for cash, or sell treasury shares, pursuant to any such offer or agreement as if this power had not expired.

This resolution is in substitution for all unexercised powers previously granted to the directors to allot equity securities as if section 561(1) of the Companies Act did not apply but without prejudice to any allotment of equity securities already made or agreed to be made pursuant to such authorities.

By order of the Board

Stephen Crowe
Company Secretary
5 June 2025

Registered office:
C/o Azets
Burnham Yard
London End
Beaconsfield
Buckinghamshire
HP9 2JH

NOTES

1. Only those members registered on the Company's register of members at:
 - close of business on Thursday 26 June 2025; or,
 - if the Meeting is adjourned, the time which is 48 hours (excluding any day which is not a working day) before the appointed time for the adjourned meeting,shall be entitled to attend and vote at the Meeting.
2. Members entitled to attend and vote at the Meeting are entitled to appoint one or more proxies to exercise all or any of their rights to attend and to speak and vote on their behalf at the Meeting and at any adjournment of it. If a proxy appointment is submitted without indicating how the proxy should vote on any resolution, the proxy will exercise his discretion as to whether and, if so, how he votes. Completion and return of a proxy form will not prevent a shareholder from attending and voting in person. If a shareholder has appointed a proxy and attends the meeting in person, his proxy appointment will automatically be terminated and votes in person will stand in its place.
3. If you do not intend to attend the Meeting in person, in order to ensure that your vote is counted, the Board recommends that the Chairman of the forthcoming Annual General Meeting is appointed as your proxy. A proxy form which may be used to make a proxy appointment and give proxy instructions accompanies this Notice. If you do not have a proxy form and believe that you should have one, or if you require additional forms, please contact Neville Registrars Limited at Neville House, Steelpark Road, Halesowen, B62 8HD. Members may also appoint a proxy through the CREST electronic proxy appointment service as described in note 6 below.
4. To appoint a proxy using the enclosed proxy form, the form must be:
 - completed and signed by or on behalf of the Member;
 - sent or delivered to Neville Registrars Limited, Neville House, Steelpark Road, Halesowen, B62 8HD (the "**Registrars**"); and
 - received by the Registrars at such address no later than 10:00 a.m. on Thursday 26 June 2025 (or, if the Meeting is adjourned, not less than 48 hours (excluding any day that is not a working day) before the appointed time for the adjourned meeting) (the "**Cut-off Time**").

In the case of a Member which is a corporation, the proxy form must be executed under its common seal or signed on its behalf by an officer of the corporation, an attorney for the corporation or any other person authorised to sign the proxy form on behalf of the corporation.

Any power of attorney or any other authority under which the proxy form is signed (or a notarially certified copy of such power or authority) must be included with the proxy form.

5. A vote withheld option is provided on the form of proxy to enable you to instruct your proxy not to vote on any particular resolution, however, it should be noted that a vote withheld in this way is not a 'vote' in law and will not be counted in the calculation of the proportion of the votes 'for' and 'against' a resolution.
6. CREST members who wish to appoint a proxy or proxies by using the CREST electronic proxy appointment service may do so for the Meeting and any adjournment(s) of it by using the procedures described in the CREST Manual (available from <https://www.euroclear.com/site/public/EUI>). CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

In order for a proxy appointment made by means of CREST to be valid, the appropriate CREST message (a "**CREST Proxy Instruction**") must be properly authenticated in accordance with Euroclear UK & International Limited's ("**EUI**") specifications and must contain the information required for such instructions, as described in the CREST Manual. The message, regardless of whether it constitutes the appointment of a proxy or an amendment to the instruction given to a previously appointed proxy, must, in order to be valid, be transmitted so as to be received by the issuer's agent (ID 7RA11) by 10:00 a.m. on Thursday 26 June 2025. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change in instructions to proxies appointed through CREST should be communicated to the appointee through other means.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that EUI does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this regard, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

7. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first-named being the most senior).
8. If a Member wishes to change his proxy instructions he should submit a new proxy appointment using the methods set out above, so as to arrive before the Cut-off Time. Any amended proxy appointment received after the Cut-off Time will be disregarded.

If a Member submits more than one valid proxy appointment in respect of the same share for use at the Meeting, the appointment received last (regardless of its date or the date of its execution) shall (provided it is received before the Cut-off Time) be treated as replacing and revoking any other proxy appointment as regards that share.

9. A Member may terminate the authority of a person to act as such Member's proxy by notice in writing to the Company delivered to the Registrars at the address specified above no later than the Cut-off Time. In the case of a Member which is a corporation, the termination notice must be executed under its common seal or signed on its behalf by an officer of the corporation, an attorney for the corporation or any other person authorised to sign such notice on behalf of the Corporation. Any power of attorney or any other authority under which the revocation notice is signed (or a notarially certified copy of such power or authority) must be included with the termination notice.
10. Any corporation which is a Member can appoint one or more corporate representatives who may exercise on its behalf all of its powers as a member provided that they do not do so in relation to the same shares.
11. Copies of the service contracts of the executive directors and letters of appointment for the non-executive directors will be available for inspection at the Meeting for at least 15 minutes prior to and during the Meeting.
12. Except as provided above, members who have general queries about the Meeting should write to the Company Secretary of the Company at c/o Azets, Burnham Yard, London End, Beaconsfield, Buckinghamshire HP9 2JH, United Kingdom. No other methods of communication will be accepted.

13. As at the close of business on the date immediately preceding this notice, the Company's issued share capital comprised 27,767,391 ordinary shares. Each ordinary share carries the right to vote at the Meeting and, therefore, the total number of voting rights in the Company as at close of business on the date immediately preceding this notice is 27,767,391.

14. Except as provided above, shareholders who wish to communicate with the Company in relation to the Meeting should do so by calling Neville Registrars Limited shareholder helpline on 0121 585 1131. If you are outside the United Kingdom please call +44 (0) 121 585 1131. Calls outside the United Kingdom will be charged at the applicable international rate. The helpline is open between 9.00 a.m. - 5.00 p.m., Monday to Friday, excluding public holidays in England and Wales. Different charges may apply to calls from mobile phones and calls may be recorded and randomly monitored for security and training purposes.

Explanatory Notes to the Business of the Annual General Meeting

Resolution 1

The Company's Annual Report and Accounts for the financial year ended on 31 December 2024 and the Directors' Report and the Independent Auditors' Report on those accounts will be presented to shareholders for approval.

Resolution 2

Although AIM traded companies are not required by company law to present a separate Remuneration Report to their shareholders for a vote, your Board has decided that the Remuneration Report, which is contained in the Annual Report, should be subject to an advisory shareholder vote. As the vote is advisory only, it does not affect the historical remuneration paid to any individual director.

Resolutions 3 and 4

At every annual general meeting at which accounts are presented to shareholders, the Company is required to appoint an auditor to serve from the conclusion of that meeting until conclusion of the next such annual general meeting. BDO LLP has confirmed that it is willing to continue as the Company's auditors for the next financial year. The Company's shareholders are asked to reappoint BDO LLP and to authorise the Audit Committee to determine their remuneration.

Resolutions 5 to 8

In accordance with Article 35.1 of the Articles and following the QCA Corporate Governance Code, each of the directors (Dr Charles Spicer, Dr Ilian Iliev, Edward Hooper and Dr Jonathan Robinson) is standing for re-appointment by the shareholders at the Meeting.

Resolution 9

Your directors may allot shares and grant rights to subscribe for, or convert any security into, shares only if authorised to do so by shareholders. The authority granted at the previous Annual General Meeting of the Company is due to expire at this year's Annual General Meeting. Accordingly, resolution 9 will be proposed as an ordinary resolution to grant new authorities to allot shares and grant rights to subscribe for, or convert any security into, shares: (a) up to an aggregate nominal amount of £462,789, representing approximately one third (33.33 per cent) of the Company's existing issued share capital as at 5 June 2025 (being the latest practicable date prior to publication of this document); and (b) in connection with a rights issue, up to an aggregate nominal amount of £925,579 (as reduced by allotments under paragraph (a) of the resolution), representing (before any reduction) approximately two thirds (66.67 per cent) of the Company's existing issued ordinary share capital as at 5 June 2025 (being the latest practicable date prior to publication of this document). Resolution 9 seeks authorities to allot shares in line with the guidance issued by the Investment Association.

Resolution 10

Generally, if the directors wish to allot new shares or other equity securities (within the meaning of section 560 of the Companies Act) for cash or sell treasury shares for cash, then under the Companies Act they must first offer such shares or securities to shareholders in proportion to their existing holdings. These statutory pre-emption rights may be disapplied by shareholders. Resolution 10, which will be proposed as a special resolution, will enable the directors to allot equity securities for cash or sell treasury shares for cash up to a maximum aggregate nominal amount of £925,579, representing, in aggregate, approximately two-thirds of the existing issued share capital without having to comply with statutory pre-emption rights.

Sub-paragraph (a) of resolution 10 allows the directors to allot equity securities for cash without complying with the statutory pre-emption rights up to an aggregate nominal amount of: (i) £925,579 in connection with a rights issue; or (ii) £462,789 in connection with an open offer or other pre-emptive offer, in each case. Sub-paragraph (b) of resolution 10 allows the directors to allot equity securities or sell treasury shares for cash without complying with the statutory pre-emption rights provided the allotment is a non-pre-emptive issue or sale for cash which is limited to securities for an aggregate nominal amount of £277,673, representing approximately 20 per cent of the issued ordinary share capital of the Company.